CHIESI FARMACEUTICI S.P.A.
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
FACTO Study (Foster® As Complete Treatment Option)
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 431
- Registration Number
- NCT00901368
- Locations
- 🇫🇷
Hôpital Nord, Marseille, France
🇳🇱Atrium Medisch Centrum Heerlen,, Heerlen, Netherlands
🇩🇪Allergologie imUmkreis der Praxis Pneumologie, Gelsenkirchen, Nordrhein-Westfalen, Germany
A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 324
- Registration Number
- NCT00885365
- Locations
- 🇫🇷
Hopital Arnaud de Villeneuve, Clinique des maladies respiratoires, Montpellier, France
🇨🇿Centrum pro cystickou fibrosu, Pediatricka klinika UK 2.LF, Fakultní nemocnice v Motole, Praha, Czechia
🇫🇷CHR Clemenceau, Caen, France
Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients
- Conditions
- Asthma
- Interventions
- Drug: Foster BDP/FormoterolDrug: CHF 1535 Next DPIDrug: Placebo
- First Posted Date
- 2009-03-24
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 69
- Registration Number
- NCT00868023
- Locations
- 🇬🇧
Pr DS SINGH, Manchester, United Kingdom
A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma
- First Posted Date
- 2009-03-16
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 783
- Registration Number
- NCT00862394
- Locations
- 🇩🇪
Oliver Kornmann - National Coordinator in Germany, Mainz, Germany
Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma
- Conditions
- Asthma
- Interventions
- Drug: Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
- First Posted Date
- 2009-03-16
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 286
- Registration Number
- NCT00862264
Study Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in Asthmatics
- First Posted Date
- 2009-03-16
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 2079
- Registration Number
- NCT00861926
- Locations
- 🇮🇹
Pr Papi, Ferrara, Italy
Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: CHF 4226 pMDIDrug: Placebo
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 20
- Registration Number
- NCT00782535
- Locations
- 🇺🇸
Clinical Research Institute of Southern Oregon, PC, Medford, Oregon, United States
🇺🇸University Clinical Research DeLand, LLC, DeLand, Florida, United States
🇺🇸New Horizons Clinical Research Center, Cincinnati, Ohio, United States
Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 47
- Registration Number
- NCT00777595
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 54
- Registration Number
- NCT00742248
- Locations
- 🇮🇹
"Centro Dipartimentale di Fisiopatologia Respiratoria", University of Genoa, Genova, Italy
Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2010-08-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 57
- Registration Number
- NCT00640484
- Locations
- 🇺🇸
Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇺🇸UCLA David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸Horizon Clinical Research Associates, PLLC, Gilbert, Arizona, United States